Former Bioasis director Nancy Stagliano's company, privately-held
Neuron23 Inc., has raised another US$100 million and has announced two small-molecule preclinical drugs. One of the drugs, NEU-723, is a small molecule that can cross the blood-brain barrier and "...targets LRRK2, a Parkinson’s disease and inflammatory disease-linked gene..."
Neuron23 uses chemical design technologies such as artificial intelligence to create small molecules that can target many diseases including neurological disorders. Small molecules can be designed to either cross the BBB or not. The manufacturing of small molecules is a chemical process, not a biological one, meaning that the small molecules do not require the significant cell-line manufacturing infrastructure that biologics require. You can read more about small-molecules vs biologics
<< here >>.
The advantage that Bioasis has with respect to the BBB is that xB3 appears to be able to transport almost any drug across the BBB. This means that the payload drug can be designed with no compromises with respect to transport across the BBB. xB3 does all the work of delivery across the BBB and the payload, no matter its size, does the disease treatment.
Small molecule drugs have to be designed to work and to be small, a compromise that is not always the most advantageous with respect to efficacy.
Neuron23's press release can be found
<< here >>.You can find the Endpoints News coverage of the story
<< here >>. Fierce Biotech covers it
<< here >>.
One of the companies participating in the financing of Neuron23 is Westlake Village BioPartners where Dr. Stagliano was previously an advisor.
jd